ArtVentive Medical Group, Inc. Featured in Scientific Session at European Vascular Conference

CARLSBAD, CA / ACCESSWIRE / March 11, 2015 / ArtVentive Medical Group, Inc. (OTCBB:AVTD) announced today that the Company’s Endoluminal Occlusion System (EOS(TM)) was featured in a presentation at the recent European Vascular Conference (EVC) in Maastricht, the Netherlands.

Dr. Krzysztof Pyra, Interventional Radiologist at the University Hospital in Lublin, Poland presented on behalf of Professor Malgorzata Szczerbo-Trojanowska and their team, the results of their initial clinical experience with the ArtVentive EOS(TM) device in the Innovative Techniques session held on Tuesday, March 10th at the EVC conference. Dr. Pyra outlined the team’s experience in using the EOS(TM) device during the treatment of pelvic congestion syndrome and varicocele.

“I am very pleased with the performance of the EOS(TM) device and we have used it in over twenty venous occlusion cases,” stated Dr. Pyra. “The immediate occlusion upon deployment provides the operator with confidence, and the ability to inject contrast through the EOS(TM) delivery catheter enhances visualization for accurate placement and deployment of the device.”

Jim Graham, Chief Executive Officer, commented: “We are pleased to have EOS(TM) device clinical experience presented to delegates at the EVC conference. The dissemination of clinical experience information, coupled with our training workshops, promotes awareness of the unique design and clinical benefits of the EOS(TM) platform. Clinical education is a key component in our efforts to support our European distribution partners as we expand commercialization efforts in the region.”

About ArtVentive Medical Group, Inc.

ArtVentive Medical Group, Inc., with corporate headquarters in Carlsbad, California, is an innovative, multi-faceted medical device company focused on developing, manufacturing and marketing globally a family of devices.

The ArtVentive EOS(TM) platform is catheter-based, self-expandable and facilitates occlusion of peripheral body lumens, cavities occurring within the body’s vascular system and organ network. The ArtVentive EOS(TM) is designed to serve as an alternative to major surgery in certain cases. This technological innovation brings current interventional, image-guided techniques to a new level of sophistication, with the potential to resolve significant, unaddressed health issues.

The ArtVentive EOS(TM) proprietary technology platform provides a foundation for future innovation and has the potential to address indications in several clinical areas, including peripheral and neurological vascular disorders, women’s health (minimally invasive contraceptive and birth control), interventional cardiology, pulmonary and interventional oncology procedures.

More information about ArtVentive can be found at www.artventivemedical.com.

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements relate to the Company’s current expectations, projections and beliefs concerning matters that are not historical facts. Forward-looking statements are not guarantees of future performance. Forward-looking statements involve uncertainties, risks, assumptions and contingencies, many of which are outside the Company’s control, and, thus, actual results could differ materially from those described in or implied by any forward-looking statement. All forward-looking statements are based on currently available information and speak only as of the date on which they are made. The Company assumes no obligation to update any forward-looking statement made in this news release that becomes untrue because of subsequent events, new information or otherwise, except to the extent it is required to do so in connection with the Company’s ongoing requirements under federal securities laws. For a further discussion of factors that could cause the Company’s future results to differ materially from any forward-looking statements, see the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission.

Contacts

ArtVentive Medical Group, Inc.
H.J. (Jim) Graham, Chief Executive Officer

Telephone: 760-471-7700
E-mail: hjgraham@artventivemedical.com

SOURCE: ArtVentive Medical Group, Inc.

ReleaseID: 426761